Particular drivers of clonal hematopoiesis are associated with a higher chance of developing myelodysplastic syndromes (MDS) and may yield significant changes in blood cell parameters, a study published in Nature Genetics suggested. The study included the medical records of 454,340 UK Biobank participants with clonal cytopenia of undetermined significance divided into 2 independent cohorts. Of all…
Researchers from France have identified a potential predictor of treatment outcomes in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) receiving azacitidine therapy. According to the study recently published in the British Journal of Haematology, half of the patients had deficient cytidine deaminase (CDA) activity (cutoff of 2 UA/mg)—an enzyme responsible for…
Several ongoing questions in the realm of myelodysplastic syndromes were discussed at the 11th Annual Meeting of the Society of Hematologic Oncology.
Luspatercept-aamt demonstrated superiority against epoetin alfa in the treatment of anemia in adults with ESA-naïve transfusion-dependent LR‑MDS.
The US Food and Drug Administration (FDA) has approved luspatercept-aamt (Reblozyl®) for the treatment of anemia without previous erythropoiesis-stimulating agent use in adult patients with myelodysplastic syndromes (MDS) who may require regular red blood cell transfusions, Bristol Myers Squibb announced. “For patients with lower-risk MDS, current standard therapies, including erythropoiesis-stimulating agents, have provided limited benefit…
A new update on the biology of myelodysplastic syndromes (MDS) suggests that interventions targeting clonal cytopenia of undetermined significance (CCUS) may lead to therapies that could improve outcomes for these patients. The update, published in Clinical Lymphoma, Myeloma, and Leukemia, notes that CCUS is a condition in which genetic mutations cause blood cell counts to…
Patients with MDS with DDX41 mutations appear to have both a germline and a somatic mutation, as well as high treatment response rates and survival.
A new study published in the American Journal of Hematology has established a novel approach to assess treatment response in patients diagnosed with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). The new response category, called peripheral blood complete remission (PB-CR), uses data from the differential blood count and clinical parameters.…
The phase 2, OPTIMIZE study is set to investigate the effectiveness of reduced dose, post-transplantation cyclophosphamide (PTCy) therapy for the prevention of graft-versus-host disease in patients with hematologic malignancies, including myelodysplastic syndromes (MDS), after receiving an HLA-mismatched unrelated donor transplantation. The study, sponsored by the Center for International Blood and Marrow Transplant Research, is not…
Researchers from Denmark have developed a novel scoring system named ProGraME that holds promise for evaluating bone marrow dysplasia in patients with myelodysplastic syndromes (MDS). In a training cohort comprising 209 patients, the ProGraME score demonstrated high sensitivity (91%) and specificity (81%), using a cutoff of 2 or higher, for dysplasia indication. The researchers further…
Please login or register first to view this content.
